linjc16/ctgov huggingface dataset:
Prevalence and Risk Factors for Postoperative Delirium 48 Hours After Surgery

Study Overview
=================
Brief Summary
-----------------
To determine the overall prevalence of postoperative delirium (POI) and its association with different risk factors in order to establish prevention plans to reduce its incidence and/or duration in Spanish hospitals. To this end, patients over 18 years of age who underwent urgent and scheduled surgery requiring hospital admission under any type of anaesthesia during two specific days will be recruited and pre-, intra- and postoperative data will be collected.

Official Title
-----------------
Prevalence and Risk Factors for Postoperative Delirium 48 Hours After Surgery: Multicenter Cohort Study.

Conditions
-----------------
Postoperative Delirium

Intervention / Treatment
-----------------
* Procedure: Any surgery under any type of anaesthesia.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 18 years of age undergoing urgent and scheduled surgery requiring hospital admission, under any type of anaesthesia. Exclusion Criteria: Presence of pre-surgical delirium. Outpatient surgery.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Single arm<br>Patients over 18 years of age undergoing urgent and scheduled surgery requiring hospital admission, under any type of anaesthesia. | Procedure: Any surgery under any type of anaesthesia.<br>* Any surgery under any type of anaesthesia.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of Postoperative Delirium in Spanish hospitals. | To determine the overall prevalence of Postoperative Delirium in Spanish hospitals. | 2 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of Postoperative Delirium by surgical speciality. | To determine the prevalence of Postoperative Delirium by surgical speciality. | 2 days | 
| Risk factors on the prevalence of Postoperative Delirium | Determine the influence of risk factors on the prevalence of Postoperative Delirium | 2 days |
Cortical Processes During Walking Post-stroke

Study Overview
=================
Brief Summary
-----------------
The study aims to use novel mobile imaging techniques with high-density electroencephalography (EEG) to quantify cortical processes synchronized to the biomechanics of walking. Here, the study has two aims - the primary aim is to quantify the cortical processes that contribute to gait dysfunction early post-stroke, and the second aim is to determine how cortical processes are mediated by mechanical assistance during early gait training post-stroke. Participants will wear an electroencephalography (EEG) cap to measure brain activity and other non-invasive physiological sensors. Participants will be asked to perform different tasks, such as walking at different speeds and walking with different levels of body weight support.

Detailed Description
-----------------
This study will recruit 15 subacute post-stroke individuals and 15 age-matched neurotypical individuals between the age of 18-80 years old.

Official Title
-----------------
Cortical Processes During Walking Post-stroke

Conditions
-----------------
Stroke, Acute, Walking, Difficulty

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria for post-stroke patients: Participants will have a unilateral brain lesion within six months prior to participation in this project; Paresis confined to one side; Ability to walk for 10 meters continuously; Absence of severe cognitive dysfunction as demonstrated by a Mini-Mental score greater than 24; Absence of severe concurrent medical problems; Ability to provide informed consent. Exclusion Criteria for age-matched adults: Any major neurological, cardiovascular, orthopedic, and psychiatric diagnoses

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Brain activity during walking measured by EEG | Changes in brain activity during walking with different levels of weight support | through study study completion, an average of 2 years | 
| Brain activity during walking measured by EEG | Differences in brain activity during walking between people post-stroke and neurotypical individuals | through study study completion, an average of 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Walking, Stroke, EEG, Assistance
Assessing the Time Demands of Cancer

Study Overview
=================
Brief Summary
-----------------
A total of 80 individuals receiving treatment for metastatic breast or advanced stage ovarian cancer will be asked to complete a baseline survey and install the mobile app on their smartphone; carry the smartphone for 28 consecutive days while outside the home; keep smartphone location and motion services active; confirm and correct (if needed) smartphone-detected activities and trips; use the app interface to provide additional information on activities and trips related to cancer treatment tasks; complete daily surveys regarding well-being; and at the end of the 28 day period, complete an online survey.

Official Title
-----------------
Time Toxicity of Cancer: the Time Demands of Cancer-related Activities and Their Impact on Well-being and Quality of Life

Conditions
-----------------
Metastatic Breast Cancer, Ovarian Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older Diagnosed with advanced stage (III, IV) ovarian (ovarian, fallopian tube or prmary peritoneal) or metastatic breast cancer [do not need to be newly diagnosed] Currently receiving any type of therapy for their cancer [can be front-line, maintenance therapy, or treatment for recurrence] Able to complete study tasks in English Able to provide voluntary informed consent Own an Android or iOS smartphone on which the operating system is version 9.0 or higher for Android or 10.0 higher for iOS; or willing to use a researcher-provided smartphone Exclusion Criteria: Those who are currently incarcerated Have opted out of research contact

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study cohort<br>Individuals receiving treatment for metastatic breast cancer or advanced stage ovarian cancer, will complete a baseline survey, install a mobile app on their smartphone to track daily activities, short daily surveys, and a study end survey | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Activity and trip types | Using the mobile app smartphone collected data, compute number of different activity or trip types. | 28 days | 
| Activity length | Using the mobile app smartphone collected data, compute the number of minutes per day spent on different activities. | 28 days | 
| Activity reoccurrence | Using the mobile app smartphone collected data, compute separate activity episodes and frequency per week. | 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ovarian cancer, metastatic breast cancer, time use, quality of life, cancer survivorship
Vascular Access Complications for Therapeutic Apheresis in Nephrology

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to describe vascular access complications which are used for therapeutic apheresis in Nephrology.

Detailed Description
-----------------
The aim of this study is to describe vascular access complications which are used for therapeutic apheresis in Nephrology. Complications may include arterio-veinous fistula or graft (AVF or AVG) thrombosis with or without known stenosis; AVF or AVG or central veinous catheter (CVC) infections and CVC dysfunctions. We may enroll all patients receveing therapeutic apheresis for nephrologic indications in our unit: Nephrologics complications include : acute or active antibody mediated rejection (ABMR), Goodpasture disease, ANCA vasculitis, thrombotic angiopathy (TMA), Focal segmental glomerulosclerosis (FSGS), HLA or ABO desensitization for kidney transplantation. Data inclusion period is from June 2020 to June 2022. The aim of the study is to describe the proportion and type of complication in our population of patient receving therapeutic apheresis. We will study the risk factors that are associated with this complications. The second aim of the study is to describe the population of patient receving therapeutic apheresis in our unit and in our region.

Official Title
-----------------
Vascular Access Complications for Therapeutic Apheresis in Nephrology : a Retrospective Observational Study in North-East France.

Conditions
-----------------
Vascular Access Complication, Apheresis Related Complication

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients in nephrology receiveing apheresis treatment by filtration or double filtration Exclusion Criteria: apheresis treatment for other indications centrifugation apheresis treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vascular access Complication rate in therapeutic apheresis | % of patient with Vascular access Complication | june 2020 june 2022 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Description of population enrolled | Description of population treated by therapeutic apheresis in Northeast France | june 2020 june 2022 | 
| Comparison of complications rate with literature datas |  | june 2020 june 2022 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Apheresis, DFPP, ANCA associated vasculitis, Goodpasture syndrome, Arterio veinous fistula, Arterio veinous graft
Effect of Opioid Cessation on Opioid-Induced Esophageal Dysfunction

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effect of opioid cessation on opioid-induced esophageal dysfunction (OIED).

Official Title
-----------------
Prospective Evaluation of the Effect of Opioid Cessation on Opioid-Induced Esophageal Dysfunction (OIED)

Conditions
-----------------
Opioid-Induced Esophageal Dysfunction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Patients enrolled in the Pain Rehabilitation Center for opioid cessation, with or without esophageal symptoms. Exclusion Criteria: Inability to provide informed consent. Patients with previous gastroesophageal surgery or pneumatic dilation. Esophageal botulinum toxin injection within the prior 12 months. Esophageal stricture Achalasia types I and II Allergy to Lidocaine or other local anesthetics Subjects on anticoagulation Bilateral nasal obstruction Pregnancy or breast feeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Opioid Cessation<br>Subjects able to complete opioid cessation. | |
| Non-Opioid Cessation<br>Subjects unable to complete opioid cessation. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects to have opioid-induced esophageal dysfunction resolution | Number of subjects to have resolution of opioid-induced esophageal dysfunction | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects with dysphagia | Number of subjects that are chronic opioid users presenting to an opioid cessation clinic to have dysphagia | 4 weeks | 
| Number of subjects with chest pain | Number of subjects that are chronic opioid users presenting to an opioid cessation clinic to have chest pain | 4 weeks | 
| Number of subjects with opioid-induced esophageal dysfunction | Number of subjects that are chronic opioid users presenting to an opioid cessation clinic to have opioid-induced esophageal dysfunction | 4 weeks |
Clinical Profile and Out Come of Children With Wilson's Disease

Study Overview
=================
Brief Summary
-----------------
Clinical profile and out come of Children with Wilson's disease :A single tertiary center study

Detailed Description
-----------------
Wilson disease (WD) is an autosomal-recessive disorder of copper metabolism caused by mutations in the ATP7B gene . It presents in childhood, adolescence or adulthood with a wide range of clinical manifestations. The disease prevalence has previously been estimated as 1 in 30,000 , but some recent analyses have suggested a genetic prevalence of 1 in 7,000 . Copper is absorbed from the stomach and duodenum, taken up by the liver, and secreted by the liver into the systemic circulation bound to ceruloplasmin ATP7B transports copper through the trans-Golgi network in hepatocytes before it is incorporated into apoceruloplasmin which is secreted as holoceruloplasmin. ATP7B is also essential for biliary excretion of copper when cytoplasmic levels are high. Dysfunction of ATP7B therefore leads to accumulation of copper in the liver giving rise to cellular damage and disease, and the release of nonceruloplasmin bound copper into the systemic circulation. Copper also accumulates and is associated with cellular damage and disease in other organs mostly in the brain Typical presentation of WD is in adolescence to early adulthood, but it may occur at any age . Clinical presentation can vary widely in terms of type and severity, but the key features are various degrees of liver disease,

Official Title
-----------------
Clinical Profile and Out Come of Children With Wilson's Disease :A Single Tertiary Center Study .

Conditions
-----------------
Clinical Outcome in WILSON Disease

Intervention / Treatment
-----------------
* Diagnostic Test: 24 hour copper in urine and liver function test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients aged 1-18 years fulfill the criteria for diagnosis of Wilson's disease according to Wilson's score Exclusion Criteria: persistent neonatal jaundice. Patients presented with Acute and chronic liver disease rather than Wilson's e.g Autoimmune hepatitis Hepatitis C virus , Hepatitis B virus infection ,(d)Hepatic focal lesions and(e) Metabolic liver disease e.g Gauchier ,glycogen storage disease and Niemman pick .

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: 24 hour copper in urine and liver function test|sampling 24 hour copper in urine and liver function test|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| COC in WILSON disease | Clinical profile and out come of Children with Wilson's disease :A single tertiary center study | Baseline |
New-onset Heart Blocks After Noncardiac Surgery: a Retrospective Study of More Than 280,000 Patients

Study Overview
=================
Brief Summary
-----------------
This study aimed to investigate new-onset heart blocks after noncardiac surgery, identify risk factors, and develop a prediction model.

Detailed Description
-----------------
Objective: This study aimed to investigate new-onset heart blocks after noncardiac surgery, identify risk factors, and develop a prediction model. Methods: A retrospective cohort study included 281,497 patients aged 18 or older who underwent noncardiac surgery at a single center between Jan 2008 and Aug 2019. The main outcome was postoperative new-onset heart blocks within one year, including atrioventricular and bundle blocks. Prognostic impact was assessed using Kaplan-Meier survival curves and time-dependent Cox regression analysis. Perioperative data was used for machine learning models (logistic regression, support vector machine, random forest, decision tree). Model performance was measured using the area under the receiver operating characteristic curve (AUC).

Official Title
-----------------
New-onset Heart Blocks After Noncardiac Surgery: a Retrospective Study of More Than 280,000 Patients

Conditions
-----------------
Heart Block, Risk Factor

Intervention / Treatment
-----------------
* Other: non interventions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients above 18 yrs undergoing noncardiac surgery at the First Medical Center of the Chinese People's Liberation Army General Hospital (PLAGH) from January 1, 2008 to August 1, 2019. Exclusion Criteria: surgical duration of less than 30 minutes incomplete data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Non- Heart blocks<br>The number of patients who did not suffered the heart blocks in the postoperative 1-year period | Other: non interventions<br> <br> |
| Heart blocks<br>The number of patients who suffered the heart blocks in the postoperative 1-year period | Other: non interventions<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| New-onset heart blocks | The number of new-onset heart blocks within one year after surgery, including first-, second-, and third-degree AV blocks and left- and right-branch bundle blocks | within one year after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Postoperative new-onset heart blocks, Noncardiac surgery, Machine learning, Prediction model, Prognosis
Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)

Study Overview
=================
Brief Summary
-----------------
This was a retrospective, observational cohort study. Data were analyzed from the Intelligent Research in Sight (IRIS) registry from October 8, 2019, through November 26, 2021, with a follow-up period of 12 months following the first brolucizumab injection (index date).

Official Title
-----------------
Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)

Conditions
-----------------
Neovascular (Wet) Age-related Macular Degeneration

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 18 years old at the time of their first (index) injection of brolucizumab. Had documented neovascular age-related macular degeneration (nAMD) on or within 3 years before the index injection. Used only brolucizumab for at least 12 months (± 45 days) after the index injection, with at least 1 brolucizumab injection given within the first 6 months after the index injection and at least 1 additional brolucizumab injection given at 6-12 months after the index injection. Exclusion Criteria: Had received any other anti-VEGF agent between the index injection and 12-month follow-up. Lacked information about the laterality of disease at the time of the index injection. Lacked visual acuity assessments on or within 30 days before the index injection or at 6, 9, and 12 months after the index injection (all of the latter ± 45 days).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Treatment-Experienced<br> | |
| Treatment-Naive<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Best Recorded Visual Acuity, Stratified by Prior Treatment Status |  | Baseline up to 12 months | 
| Change in Injection Interval at 12 Months of Brolucizumab Treatment Compared with Prior Anti-vascular Endothelial Growth Factor (VEGF) Treatment |  | Baseline up to 12 months | 
| Number of eyes with adverse events |  | Baseline up to 12 months | 
| Time to adverse event |  | Baseline up to 12 months | 
| Number of brolucizumab injections prior to adverse event |  | Baseline up to 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Brolucizumab Injection Interval and Interval Extension, Stratified by Pre-Switch Interval |  | Baseline up to 12 months |